Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This is an international open-label, randomized, multicenter phase II study of VIT and VI for
the treatment of patients with recurrent or refractory rhabdomyosarcoma. The study will
evaluate the safety and efficacy of these combinations in patients with recurrent or
refractory rhabdomyosarcoma.